Richard Southworth

Dr. Richard Southworth


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2006 in Cardiovascular Research
Verified
Journal Article
Closed access
JBJ Brennan
J Brennan
RSRichard Southworth
Richard Southworth
RMR Medina
R Medina
SDS Davidson
S Davidson
MDM Duchen
M Duchen
MSM Shattock
M Shattock
Both K(ATP) channel opening drugs and ischaemic preconditioning have been suggested to protect the ischaemic heart by acting on K(ATP) channels in the inner mitochondrial membrane, uncoupling the proton gradient and partially dissipating the mitochondrial membrane potential. The aim of these studies was to use low concentrations of FCCP, a mitochondrial protonophore, to bypass the mitochondrial K(ATP) channel and partially uncouple the mitochondria and establish whether this activates protective pathways within the rat heart analogous to K(ATP) channel openers or preconditioning. Isolated, Langendorff-perfused rat hearts were subjected to 25 min global zero-flow ischaemia and functional recovery assessed. Hearts were pretreated with FCCP (30-300 nM) in the presence or absence of glibenclamide (1 microM), 5-hydroxydecanoate (5-HD: 100 microM), N-acetyl cysteine (4 mM), or N-2-mercaptopropionyl glycine (1 mM). The metabolic consequences of FCCP perfusion in isolated hearts were studied using (31)P NMR, and reactive oxygen species (ROS) production was measured using DCF fluorescence in isolated rat ventricular myocytes. FCCP exerted a dose-dependent cardioprotective effect, with 100 nM FCCP being the optimal concentration. This effect could not be blocked by glibenclamide or 5-HD, but was completely attenuated by N-acetyl cysteine and N-2-mercaptopropionyl glycine. Perfusion with FCCP (100 nM) did not deplete bulk ATP during the pretreatment period but significantly depleted phosphocreatine. In ventricular myocytes, FCCP caused an antioxidant-sensitive increase in ROS production but diazoxide was without effect. In the isolated rat heart, partial mitochondrial uncoupling with low-dose FCCP significantly improves post-ischaemic functional recovery via a ROS-dependent pathway. This cardioprotection is not mediated via the depletion of cellular ATP or mitochondrial K(ATP) channel activation.

28 March 2014 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
RNRianne Nederlof
Rianne Nederlof
OEOtto Eerbeek
Otto Eerbeek
MHMarkus W Hollmann
Markus W Hollmann
RSRichard Southworth
Richard Southworth
CZCoert Zuurbier
Coert Zuurbier

13 May 2011 in Circulation Research
Verified
Journal Article
Closed access
KSKirsten M.A. Smeele
Kirsten M.A. Smeele
RSRichard Southworth
Richard Southworth
RWRongxue Wu
Rongxue Wu
CXChaoqin Xie
Chaoqin Xie
RNRianne Nederlof
Rianne Nederlof
CZCoert J. Zuurbier
Coert J. Zuurbier
Rationale:: Isoforms I and II of the glycolytic enzyme hexokinase (HKI and HKII) are known to associate with mitochondria. It is unknown whether mitochondria-bound hexokinase is mandatory for ischemic preconditioning and normal functioning of the intact, beating heart. Objective:: We hypothesized that reducing mitochondrial hexokinase would abrogate ischemic preconditioning and disrupt myocardial function. Methods and Results:: Ex vivo perfused HKII +/− hearts exhibited increased cell death after ischemia and reperfusion injury compared with wild-type hearts; however, ischemic preconditioning was unaffected. To investigate acute reductions in mitochondrial HKII levels, wild-type hearts were treated with a TAT control peptide or a TAT-HK peptide that contained the binding motif of HKII to mitochondria, thereby disrupting the mitochondrial HKII association. Mitochondrial hexokinase was determined by HKI and HKII immunogold labeling and electron microscopy analysis. Low-dose (200 nmol/L) TAT-HK treatment significantly decreased mitochondrial HKII levels without affecting baseline cardiac function but dramatically increased ischemia-reperfusion injury and prevented the protective effects of ischemic preconditioning. Treatment for 15 minutes with high-dose (10 μmol/L) TAT-HK resulted in acute mitochondrial depolarization, mitochondrial swelling, profound contractile impairment, and severe cardiac disintegration. The detrimental effects of TAT-HK treatment were mimicked by mitochondrial membrane depolarization after mild mitochondrial uncoupling that did not cause direct mitochondrial permeability transition opening. Conclusions:: Acute low-dose dissociation of HKII from mitochondria in heart prevented ischemic preconditioning, whereas high-dose HKII dissociation caused cessation of cardiac contraction and tissue disruption, likely through an acute mitochondrial membrane depolarization mechanism. The results suggest that the association of HKII with mitochondria is essential for the protective effects of ischemic preconditioning and normal cardiac function through maintenance of mitochondrial potential.

1 October 2010 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
ASAndreas Schuster
Andreas Schuster
IGInga Grünwald
Inga Grünwald
ACAmedeo Chiribiri
Amedeo Chiribiri
RSRichard Southworth
Richard Southworth
MIMasaki Ishida
Masaki Ishida
ENEike Nagel
Eike Nagel
Novel cardiovascular magnetic resonance (CMR) techniques and imaging biomarkers are often validated in small animal models or empirically in patients. Direct translation of small animal CMR protocols to humans is rarely possible, while validation in humans is often difficult, slow and occasionally not possible due to ethical considerations. The aim of this study is to overcome these limitations by introducing an MR-compatible, free beating, blood-perfused, isolated pig heart model for the development of novel CMR methodology.

1 September 2009 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
RSRichard Southworth
Richard Southworth
MKMegan Kaneda
Megan Kaneda
JCJunjie Chen
Junjie Chen
LZLei Zhang
Lei Zhang
HZHuiying Zhang
Huiying Zhang
SWSamuel A. Wickline
Samuel A. Wickline

1 January 2007 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
RSRichard Southworth
Richard Southworth
KDKatherine A. B. Davey
Katherine A. B. Davey
AWAlice Warley
Alice Warley
PGPamela B. Garlick
Pamela B. Garlick
Hexokinase is responsible for glucose phosphorylation, a process fundamental to regulating glucose uptake. In some tissues, hexokinase translocates to the mitochondria, thereby increasing its efficiency and decreasing its susceptibility to product inhibition. It may also decrease free radical formation in the mitochondria and prevent apoptosis. Whether hexokinase translocation occurs in the heart is controversial; here, using immunogold labeling for the first time, we provide evidence for this process. Rat hearts (6 groups, n = 6/group), perfused with either glucose- or glucose + oleate (0.4 mmol/l)-containing buffer, were exposed to 30-min insulin stimulation, ischemia, or control perfusion. Hexokinase I (HK I) and hexokinase II (HK II) distributions were then determined. In glucose-perfused hearts, HK I-mitochondrial binding increased from 0.41 ± 0.04 golds/mm in control hearts to 0.71 ± 0.10 golds/mm after insulin and to 1.54 ± 0.38 golds/mm after ischemia ( P < 0.05). Similarly, HK II-mitochondrial binding increased from 0.16 ± 0.02 to 0.53 ± 0.08 golds/mm with insulin and 0.44 ± 0.07 golds/mm after ischemia ( P < 0.05). Under basal conditions, the fraction of HK I that was mitochondrial bound was five times greater than for HK II; insulin and ischemia caused a fourfold increase in HK II binding but only a doubling in HK I binding. Oleate decreased hexokinase-mitochondrial binding and abolished insulin-mediated translocation of HK I. Our data show that mitochondrial-hexokinase binding increases under insulin or ischemic stimulation and that this translocation is modified by oleate. These events are isoform specific, suggesting that HK I and HK II are independently regulated and implying that they perform different roles in cardiac glucose regulation.